In this article, we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.
Diffuse Large B-Cell Lymphoma
Antiretroviral therapy and rituximab show promise in aids-related diffuse large B-cell lymphoma patients.
A study shows pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in lymphomas.
Recent studies on CAR T-cell immunotherapy, and the recent approval of a new agent, add to evidence supporting the efficacy of these therapies.
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.